Printer Friendly

US FDA grants priority review designation for Tesaro's Zejula.

M2 EQUITYBITES-June 26, 2019-US FDA grants priority review designation for Tesaro's Zejula

(C)2019 M2 COMMUNICATIONS http://www.m2.com

The United States Food and Drug Administration (FDA) has granted priority review designation for United States-based Tesaro's (PARP) polymerase inhibitor Zejula (niraparib) intended for the treatment of late stage ovarian cancer, it was reported yesterday.

According to the supplemental new drug application (sNDA) submitted to the regulator, the company is seeking approval of the product for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer in patients who were earlier subjected to three or more prior chemotherapy regimens. More specifically, the approval for the polymerase inhibitor is being sought for such patients whose cancer is associated with either BRCA mutation or homologous recombination deficiency (HRD) with their condition progressed more than six months following the last platinum-based chemotherapy.

In the mid-stage trial, the drug indicated activity in the primary efficacy population of fourth and fifth-line HRD positive patients who were PARP inhibitor naive, and platinum sensitive. The objective response rate (ORR) was 29%, while the duration of response (DOR) was 9.2 months. In patients, who were fourth line or greater with BRCA mutations, including platinum-sensitive, resistant and refractory, the ORR was 31%, while the median DOR was 9.4 months.

Tesaro president and chief operating officer, Mary Lynne Hedley, said, 'The results of the QUADRA study demonstrate that ZEJULA is active as a late-line treatment for patients beyond those with BRCA mutations. With this study, we continue to advance our mission to provide more patients with ovarian cancer an opportunity to benefit from treatment with ZEJULA.'

Tesaro is a GlaxoSmithKline company.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jun 26, 2019
Words:285
Previous Article:Skoda Auto India to offer discounts on L&K variants of certain models.
Next Article:BMW to launch 2020 X1 facelift in Munich.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters